The Federal Circuit held that the University of Texas’s drug-releasing fiber patent claims were anticipated by a single prior art reference and that Boston Scientific’s stent coating did not infringe. The precedential ruling erased a jury award of roughly $50 million including interest.

Read more: https://www.cafc.uscourts.gov/opinions-orders/24-2062.OPINION.7-27-2026_2728460.pdf